Lv1
67 积分 2023-03-16 加入
Beyond Surveillance, Epidemiology, and End Results data: Clinical trial landscape and biological considerations in Merkel cell carcinoma
5天前
已完结
Toward a More Nuanced Approach: Unaddressed Gaps in Monitoring Recommendations for Psoriasis Biologics
5天前
已完结
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
11天前
已完结
A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial
18天前
已关闭
Feasibility of using OGTT 1-h PG as a diagnostic criterion for diabetes and pre-diabetes
18天前
已关闭
Interleukin 23 inhibitors for psoriasis: not just another number
18天前
已关闭
Interleukin 23 inhibitors for psoriasis: not just another number
18天前
已关闭
A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis
19天前
已完结
A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis
20天前
已关闭
A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis
21天前
已关闭
皖公网安备34019202002308
